NCT06666413View on ClinicalTrials.gov

China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD

PHASE4RecruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

May 7, 2025

Primary Completion Date

May 2, 2028

Study Completion Date

May 2, 2028

Conditions
Glycogen Storage Disease Type IIPompe's Disease
Interventions
DRUG

Avalglucosidase alfa

Pharmaceutical form: Sterile lyophilized powder Route of administration: IV infusion

Trial Locations (1)

200127

RECRUITING

Investigational Site Number: 1560001, Shanghai

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT06666413 - China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD | Biotech Hunter | Biotech Hunter